Follow us on Facebook!
Follow us on Twitter!
Follow us on Youtube!

Recent news

News archive

Prothena Corporation, a pharmaceutical company in neuroscience and orphan disease, has announced that it is discontinuing development of NEOD001, a drug being researched in clinical trials for the treatment of AL amyloidosis patients. The decision was taken because NEOD001 did not do as well as expected in its clinical development programme. Continue reading

Plitidepsin (Aplidin®), a new medicine for the treatment of relapsed and refractory myeloma, has today received a second negative recommendation from the Committee for Medicinal Products for Human Use (CHMP). This decision means that plitidepsin is very unlikely to made available to patients across Europe.

This upholds a previous negative recommendation from the CHMP, which was reviewed following an appeal by the pharmaceutical company Pharma Mar.

Continue reading

Today marks the official launch of a new international project consortium, known as “CARAMBA”, which will research an innovative immunotherapy for the treatment of multiple myeloma, known as Chimeric Antigen Receptor T-cell therapy (CAR-T). Through strategic collaboration with a wide-range of stakeholders, the consortium aims to ensure the streamlined transition of CAR-T from the laboratory through to multiple myeloma patients in the clinic. Continue reading

MPE is inviting members to express their interest in participating in a small pilot on patient information for newly diagnosed myeloma patients.

As part of this pilot, MPE will be adapting and translating an Infopack for newly diagnosed patients (created by Myeloma UK) for use in small group of European countries. The Infopack provides information that patients may need to know following the diagnosis of myeloma and provides practical tips.

Continue reading

Myeloma Patients Europe will hold an online webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in San Diego (California, United States) in December 2017.

The talk will be given by Dr María Victoria Mateos, Associate Professor of Hematology and Consultant. Physician of the Haematology Department at the University Hospital of Salamanca, Spain. Continue reading

Myeloma Patients Europe (MPE) has written to the Chair of the Committee for Human Medicinal Products for Human Use (CHMP) within the European Medicines Agency (EMA) to provide the patient viewpoint on the importance of plitidepsin (Aplidin®) for relapsed and refractory myeloma patients across Europe. We have outlined how important it is for patients across Europe to gain access to effective drugs that have new mechanisms of action. Continue reading